Sp1250
SPECTRUM OF ESOPHAGEAL MOTOR DYSFUNCTION IN EOE AND GERD
Date
May 9, 2023
Explore related products in the following collection:
Tracks
Related Products
IMPACT OF UP TO 6 MONTHS OF MEPOLIZUMAB TREATMENT FOR ADOLESCENTS AND ADULTS WITH EOSINOPHILIC ESOPHAGITIS IN THE SECOND PHASE OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
EFFICACY AND SAFETY OF BENRALIZUMAB IN ADULTS AND ADOLESCENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 24-WEEK DOUBLE-BLIND PERIOD OF THE PHASE 3 MESSINA TRIAL
BACKGROUND: Tools predicting incident esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA) that can be automated in electronic health records (EHRs) to guide screening decisions are needed…
LONGITUDINAL EFFECTS OF TREATMENT ON ESOPHAGEAL DYSMOTILITY IN EOSINOPHILIC ESOPHAGITIS
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
<i>THE SEVERITY OF REDUCED ESOPHAGEAL DISTENSIBILITY PARALLELS EOSINOPHILIC DISEASE DURATION</i>
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy…